Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Deferred Taxes (2023 - 2024)

Historic Deferred Taxes for Xeris Biopharma Holdings (XERS) over the last 2 years, with Q3 2024 value amounting to -$3.3 million.

  • Xeris Biopharma Holdings' Deferred Taxes fell 59244.44% to -$3.3 million in Q3 2024 from the same period last year, while for Jun 2025 it was -$3.3 million, marking a year-over-year decrease of 78962.66%. This contributed to the annual value of -$2.3 million for FY2024, which is 8158.53% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Deferred Taxes of -$3.3 million as of Q3 2024, which was down 59244.44% from $749000.0 recorded in Q2 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Deferred Taxes ranged from a high of $749000.0 in Q2 2024 and a low of -$3.3 million during Q3 2024